Specialty pharmaceutical company Supernus has launched Trokendi XR, its once-daily extended release formulation of topiramate, for the treatment of epilepsy in the US.
As of now, Trokendi XR has been shipped to major wholesalers in the market, while the company's sales force is promoting the product to physicians.
Supernus president and CEO Jack Khattar said, "Supernus is now a major player in epilepsy, offering two novel and differentiated products to patients."
The antiepileptic drug (AED) is indicated for initial monotherapy in patients aged 10 years and more with partial onset or primary generalized tonic-clonic seizures; adjunctive therapy in patients aged six years and more with partial onset or primary generalized tonic-clonic seizures.
Additionally, Trokendi XR is indicated as adjunctive therapy in patients aged six years and more with seizures associated with Lennox-Gastaut syndrome.
Approved for use as recommended in the agreed-upon labeling, the drug is available in 25mg, 50mg, 100mg and 200mg extended-release capsules.
